Prothena Corporation plc

NASDAQ:PRTA

Biotechnology

Healthcare
$8.35 +3.89%

+$0.33 today

Market cap
$428.77M
Beta
-0.32
P/E (TTM)
-3.1
EPS (TTM)
-$2.81
52W Low $5.64High $11.80

Volume 0.76M

Average 0.51M

PRTA Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Prothena Corporation plcNASDAQ: PRTA

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development declines year over year

Q1 FY2026 research & development of $12.63M fell 75.1% year over year, behind the -53.8% change in trailing-twelve-month research & development. Sequentially, it fell 13.4% from the prior quarter. Over 3 fiscal years it compounded at -0.2% a year.

Context

  • Research & development amounted to 1392.5% of revenue in FY2025, up 1227.9 pp from a year earlier.
  • Research & development increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -75.1% toward the trailing-twelve-month pace of -53.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$12.63M-13.4% QoQ
Last fiscal yearDec 2025
$134.85M-39.4% YoY
LTMMar 2026
$96.67M-53.8% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-75.1%——
1 year-39.4%——
3-year CAGR-0.2%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
134.85M USD
Year-over-year change
-39.4%
4-year CAGR
+13.1%

Research & Development vs competitors

How PRTA compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -53.8% is the lowest of 10, against a peer median of -17.6%.
  • Research & development amounts to 166.8% of revenue for PRTA, versus a peer median of 1409.6%.
PRTA Competitors
Research & Development for PRTA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BIIBBiogen Inc.LTM Jun 2026$1.95B USD-19.9%-9.0%19.6%
DNLIDenali Therapeutics Inc.LTM Jun 2026$400.72M USD-3.9%+5.3%11118.8%
ANNXAnnexon, Inc.LTM Mar 2026$172.31M USD+17.5%+18.0%—
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026$162.51M USD-21.6%+18.9%—
PRTAProthena Corporation plcLTM Mar 2026$96.67M USD-53.8%-0.2%166.8%
ABOSAcumen Pharmaceuticals, Inc.LTM Mar 2026$96.1M USD-9.9%+48.0%—
ACIUAC Immune S.A.LTM Mar 2026CHF 52.18M CHF-17.6%-2.2%1409.6%
PMNProMIS Neurosciences, Inc.LTM Jun 2026$35.66M USD+69.0%-87.2%—
CGTXCognition Therapeutics, Inc.LTM Mar 2026$32.45M USD-22.6%+7.0%—
AVXLAnavex Life Sciences Corp.LTM Dec 2025$31.8M USD-27.0%-0.3%—
Peer median (excluding PRTA) —-17.6%+5.3%1409.6%

Competitors are the stored peer set for PRTA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue200.58M53.91M91.37M135.16M9.68M
Cost of Revenue00003.7M
Gross Profit200.58M53.91M91.37M135.16M5.98M
Gross Margin100.0%100.0%100.0%100.0%61.8%
Research & Development82.28M135.56M220.57M222.52M134.85M
Selling, General & Admin46.32M49.9M61.84M67.2M59.39M
Operating Expenses128.6M185.46M282.41M289.72M190.54M
Depreciation & Amortization1.12M744K928K893K3.7M
EBITDA73.04M(124.86M)(159.55M)(128.04M)(197.13M)
EBITDA Margin36.4%-231.6%-174.6%-94.7%-2035.6%
Operating Income71.98M(131.56M)(191.04M)(154.56M)(184.56M)
Operating Margin35.9%-244.1%-209.1%-114.4%-1905.8%
Interest Income42K6.35M31.01M25.82M14.14M
Interest Expense00000
Other Income / Expenses(54K)5.95M30.56M25.63M(16.27M)
Income Before Tax71.92M(125.61M)(160.48M)(128.93M)(200.83M)
Pre-Tax Margin35.9%-233.0%-175.6%-95.4%-2073.8%
Income Tax Expense4.95M(8.66M)(13.45M)(6.62M)43.26M
Net Income66.98M(116.95M)(147.03M)(122.31M)(244.09M)
Net Margin33.4%-217.0%-160.9%-90.5%-2520.6%
EPS (Basic)1.51(2.47)(2.76)(2.27)(4.53)
EPS (Diluted)1.38(2.47)(2.76)(2.27)(4.53)
Weighted Avg Shares44.23M47.37M53.22M53.77M53.83M
Weighted Avg Shares (Diluted)48.46M47.37M53.22M53.77M53.83M

Prothena Corporation plc

NASDAQ:PRTA

Intrinsic Alpha fair value

Locked

Current Price

$8.35

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.